CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 6 enrolled
Drug / intervention
Fingolimoddrug
Likely dose
Fingolimod 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02232061
NCT02232061Phase 4Completed
CompareCT.gov

Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod

Novartis Pharmaceuticals·interventional·Posted Sep 4, 2014·Updated Feb 10, 2021

In Brief

A Phase 4 clinical trial evaluating Fingolimod for Multiple Sclerosis. Completed, enrolled 6 participants across 4 sites in 3 countries.

Detailed Summary

This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesBelgium, Germany, Italy
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 4, 2014
Enrollment StartSep 29, 2014
Primary CompletionJan 24, 2020
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 11.8 years ago

Interventions

Fingolimoddrug

Fingolimod 0.5 mg tablet